Digital Therapeutics and Psychedelic Medicines || MindMed’s SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai’s secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface.

Instead of doing our usual “This Week In Psychedelic Stocks episode”, I decided to discuss the article entitled “Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP” as it pertains to MindMed and Atai and because there wasn’t a lot of interesting news for our usual Psychedelic segment.

Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there’s two reasons.

1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare.
2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology.

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

If you wish to collaborate, send us an email at:
thepsychedelicinvestor@gmail.com

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

Music: www.bensound.com

Time Stamps:

0:00 – Intro
10:08 – Implications for MindMed and Atai

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​#MindmedStock​​ #MMEDNews

Similar Posts

Psychedelic Stocks in the Short-Term: Expectations, Catalysts, Risks and Reward

Psychedelic Stocks in the Short-Term: Expectations, Catalysts, Risks and Reward

Listen, Videos

When it comes to investing in psychedelic stocks such as MindMed (MNMD, MMED), Compass Pathways (CMPS), atai Life Sciences (ATAI), Cybin (CYBN) and more, even if we have a solid long term thesis, the short term is very volatile.

To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

PS: THIS IS NOT INVESTING ADVICE, JUST MY OPINION.

In this video, I will discuss what to look out for, both the positives and the negatives, in the coming months. What are the catalysts? What are the risks?
The main thing to understand, is that the market cares more about short term profit than it does long term indicators. Right now, we are seeing psychedelic medicine clinical trials showing fantastic results, but we should not expect the market to react until we are closer to commercialization.
There are also many macro risks to be aware of, and general all around volatility. But we need to remember, short term swings do not affect the long-term thesis.

Links:
Awakn Phase 2 Ketamine Therapy for Alcohol Use Disorder:
https://psychedelicspotlight.com/ketamine-trial-alcohol-use-disorder-promising-results-awakn-life-sciences/

MAPS Phase 3 MDMD for PTSD Trial
https://psychedelicspotlight.com/first-phase-3-trial-mdma-assisted-therapy-ptsd/

Compass Pathways Phase 2b Psilocybin for Depression Trial
https://psychedelicspotlight.com/compass-pathways-largest-psilocybin-therapy-trial-ever-depressive-symptoms-rapidly-reduce/

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#PsychedelicStocks #MindMed #Cybin

AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

Learn, Videos

AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results) Today, we’ll be sharing some GAME changing news for the entire psychedelic-medicines industry!

First, we’ll start with some inspiring results from a few MDMA studies and their implications for companies such as Numinus (NUMI), MindMed (MMED / MNMD / MMQ) and Atai Life Sciences. First we’ll cover MAPS’ Phase III MDMA To Treat PTSD Trial Results. Then, we’ll focus on another study’s results, which implies that MDMA could be an effective treatment for alcoholism.

Then, we’ll shift our focus towards an update on Texas, one of the more conservative U.S. states, and its approval of a Psychedelics Research Bill.

Finally, we’ll share some of the oddest and most exciting news from this week: AI might potentially disrupt the psychedelic industry in the next few decades through the creation of psychedelic medicines.

Timestamps:

0:00 – Intro
1:24 – Maps Phase III Trial Testing MDMA to treat PTSD RESULTS & Implications for
Numinus (NUMI), MindMed (MMED / MNMD / MMQ ), Atai, etc.
3:23 – Imperial College of London Study testing MDMA-assisted psychotherapy to treat Alcoholism
7:29 – Texas House Approves a Psychedelic Research Bill
9:34 – Scientists are Using AI to Develop New Psychedelic Drugs

Links to Maps Phase III MDMA trial to treat PTSD : https://www.nytimes.com/2021/05/03/health/mdma-approval.html
https://maps.org/news/media/9122-maps-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-achieves-successful-results-for-patients-with-severe-chronic-ptsd

Links to the Imperial College of London MDMA study to treat alcoholism: https://www.telegraph.co.uk/health-fitness/body/mdma-cured-alcoholism-inside-remarkable-ectsasy-trial-offering/
https://www.telegraph.co.uk/news/2021/02/22/mdma-could-used-treat-alcohol-addiction/

Link to the Texas House Psychedelics Research Bill: https://www.marijuanamoment.net/texas-house-approves-psychedelics-research-bill-as-marijuana-reform-measures-also-advance/

Link to the article “Scientists are Using AI to Develop New Psychedelic Drugs: https://doubleblindmag.com/artificial-intelligence/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #MNMD